Transscleral Diode Laser Cyclophotocoagulation: A Comparison of Slow Coagulation and Standard Coagulation Techniques
Overview
Authors
Affiliations
Purpose: To compare the outcomes of standard pop-titrated transscleral cyclophotocoagulation (TSCPC) and slow-coagulation TSCPC in the treatment of glaucoma.
Design: Retrospective case series.
Subjects: This study included 78 eyes with glaucoma of any type or stage that underwent TSCPC as part of their treatment course.
Methods: This study compared 52 eyes treated with slow coagulation TSCPC to 26 eyes treated with standard pop-titrated TSCPC. Patient demographics, treatment course, surgical techniques, settings and outcomes were assessed.
Main Outcome Measures: The main outcome measures were visual acuity (VA), intraocular pressure (IOP) and post-surgical complications.
Results: The initial LogMAR VA was 1.94 (0.73) [mean (SD)] in the slow coagulation TSCPC group and 1.71 (0.90) in the standard TSCPC group (p=0.507). Initial IOP was 37 (13) mm Hg in the slow coagulation group and 39 (13) mm Hg in the standard group (p=0.297). The follow-up periods were 16.36 months and 24.68 months for the slow coagulation and standard groups (p=0.124). VA remained better than light-perception in 71.1% of slow coagulation treated patients and 65.0% of standard TSCPC treated patients (p=0.599). IOP remained below 20 mm Hg in 46% of slow coagulation treated patients and 44% of standard TSCPC treated patients (p=0.870). The mean number of complications was higher in the standard group [1.46 (1.24)] versus the slow coagulation group [0.62 (0.75)] (p=0.002). The incidence of the need for a second procedure (slow coagulation- 28.8%, standard- 23.1%, p=0.588) and maximum number of medications needed to control IOP postoperatively (p=0.771) were similar between the two groups.
Conclusions: In this case series, slow coagulation TSCPC and standard pop-titrated TSCPC resulted in similar VA and IOP outcomes in the treatment of glaucomatous eyes. The complication profiles of the techniques were also comparable, although standard TSCPC had a higher incidence of prolonged inflammation postoperatively. This study suggests that slow coagulation TSCPC may achieve equivalent control of IOP while reducing the incidence of prolonged post-operative inflammation-a feared complication of TSCPC-when compared to standard "pop-titrated" TSCPC.
Radhakrishnan S, Kots-Gotlib N, Pickering T, McCurdy J, Siu J, Pham D Clin Ophthalmol. 2024; 18:3825-3836.
PMID: 39712369 PMC: 11662913. DOI: 10.2147/OPTH.S498973.
Hwang Y, Lee S, Kim M, Choi J Sci Rep. 2024; 14(1):23944.
PMID: 39397105 PMC: 11471840. DOI: 10.1038/s41598-024-75246-y.
Efficacy and Safety of Diode Laser Transscleral Cyclophotocoagulation in Patients with Glaucoma.
Ribeiro M, Freitas J, Lima-Fontes M, Leuzinger-Dias M, Silva M, Araujo J Clin Ophthalmol. 2024; 18:2271-2279.
PMID: 39161366 PMC: 11330864. DOI: 10.2147/OPTH.S473788.
Parekh Z, Wang J, Qiu M Am J Ophthalmol Case Rep. 2024; 35:102072.
PMID: 38841152 PMC: 11152606. DOI: 10.1016/j.ajoc.2024.102072.
Cyclophotocoagulation in Neovascular Glaucoma with Near-Total Synechial Angle Closure.
Wang J, Chun L, Qiu M Case Rep Ophthalmol Med. 2023; 2023:5719002.
PMID: 37929013 PMC: 10622186. DOI: 10.1155/2023/5719002.